Dyne Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
DYN Nasdaq 8731 https://dyne-tx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dyne Therapeutics Inc

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference - Sep 23rd, 2024 12:56 pm
CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares - Sep 6th, 2024 10:39 am
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More - Sep 5th, 2024 3:15 pm
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down - Sep 4th, 2024 4:58 pm
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes - Sep 4th, 2024 1:10 pm
High-dose Spinraza meets study goal; Top Dyne executives exit - Sep 4th, 2024 12:15 pm
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy - Sep 3rd, 2024 4:37 pm
Dyne Therapeutics Announces Key Leadership Appointments - Sep 3rd, 2024 10:31 am
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts - Sep 3rd, 2024 10:30 am
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - Aug 29th, 2024 11:30 am
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Aug 12th, 2024 9:10 pm
Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why - Jul 29th, 2024 12:50 pm
What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now? - Jul 18th, 2024 4:00 pm
Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why - Jul 12th, 2024 12:50 pm
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease - Jun 24th, 2024 11:30 am
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress - Jun 13th, 2024 8:40 pm
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference - May 30th, 2024 11:30 am
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - May 28th, 2024 11:30 am
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock - May 22nd, 2024 12:39 am
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies - May 21st, 2024 4:27 pm